ライフサイエンスコーパス: Fc fragment

1 he Calpha2-Calpha3 interdomain region in the Fc fragment.

2 antennae in mCrry-Ig were extended from the Fc fragment.

3 itis B virus (HBV) e antigen fused to an IgG Fc fragment.

4 at the C terminus of each heavy chain in the Fc fragment.

5 in one F(ab')2 molecule and one homodimeric Fc fragment.

6 us type-2 (HSV-2) glycoprotein gD, to an IgG Fc fragment.

7 perties of sc-gAd further, we fused it to an Fc fragment.

8 of the omalizumab-Fab in complex with an IgE-Fc fragment.

9 ialylation of the N-linked glycan of the IgG Fc fragment.

10 ct molecule, suggesting participation of the Fc fragment.

11 family of Fab-like fragment relative to the Fc fragment.

12 s of the hinge peptide joining the mCrry and Fc fragments.

13 on the anti-inflammatory activity of IVIG or Fc fragments.

14 "closed" anti-inflammatory state of antibody Fc fragments.

15 nicity, and yields therapeutic F(ab')(2) and Fc fragments.

16 hinge lysine 222 residue, generating Fab and Fc fragments.

17 preparation of appropriately sialylated IgG Fc fragments.

18 -inflammatory activity of IVIG or sialylated Fc fragments.

19 ain at position 222, generating free Fab and Fc fragments.

20 tructures for the CR2 SCR 1-2 and mouse IgG1 Fc fragments.

21 pes, with 64 residues connecting the Fab and Fc fragments.

22 inge region, which joins the two Fab and one Fc fragments.

23 cFv-C(H)3 dimer; 80 kDa) and a modified scFv-Fc fragment (105 kDa), designed to clear rapidly, were g

24 or as a fusion protein with the murine IgG2a Fc fragment (47-LDA-Fcgamma2a) to deliver the antigenic

25 pen V-shape in random orientations about the Fc fragment accounted for the scattering and sedimentati

26 GFR2/Ad Flk1-Fc), a control murine IgG2alpha Fc fragment (Ad Fc), or vehicle (phosphate-buffered sali

27 o be very similar to those of the free human Fc fragment, although differences are present in the ter

28 four-domain Fab fragments and a four-domain Fc fragment analogous to that in immunoglobulin G (IgG),

29 display peptide which binds a human antibody Fc fragment and creating a backbone cyclic beta-hairpin

30 tecting weak binding between full-length IgG/Fc fragments and Fc receptors and the effect of chemical

31 observed at the N-terminal residues of some Fc fragments and were identified as isocyanate and alpha

32 allowing us to engineer an appropriate IgG1 Fc fragment, and thus generate a fully recombinant, sial

33 bodies against IL6, soluble glycoprotein 130 Fc fragments, and the signal transducers and activators

34 fied the solution arrangement of its Fab and Fc fragments, and thereby its hinge structure.

35 erapeutic intravenous gamma globulin and its Fc fragments are anti-inflammatory.

36 The corresponding Fab+Fc fragment beginning with cys-218 was not found.

37 In addition, FREB lacks bona fide Fc fragment binding regions and does not bind immunoglob

38 Killing was prevented by DcR3-Fc fragment but not control human-Fc fragment, showing t

39 tion time, for example, rapid removal of the Fc fragment by IdeS digestion, minimizes assay artifacts

40 d IgA1 hinge structures to which the Fab and Fc fragments could be connected in any orientation.

41 residues on the N-linked glycans of the IgG Fc (fragment crystallizable) domain.

42 ubpicomolar affinity for IL-6, combined with Fc (fragment crystallizable) engineering to enhance phar

43 The antibody Fc (fragment crystallizable) region is a vital component

44 We administered CSF1-Fc (fragment, crystallizable) to mice after partial hepa

45 ect plaque erosion using (64)Cu-labeled GPVI-Fc (fragment crystallized).

46 eering technology is a powerful tool for IgG Fc (fragment cystallizable) N-glycosylation remodeling.

47 is observation, phage display of mutagenized Fc fragments derived from a human IgG1 was used to incre

48 erodimeric and homodimeric "knob" and "hole" Fc fragments derived from bacterial expression.

49 protein containing RBD linked to human IgG1 Fc fragment (designated RBD-Fc) induced high titer of RB

50 Fc fragments did not modulate any of these parameters.

51 as a target for Ag delivery using engineered Fc fragment-epitope fusions.

52 ory activities through the engagement of its Fc fragment (Fc) with distinct Fcg receptors (FcgRs).

53 Recent studies have demonstrated that IgG-Fc fragments (Fcabs) can be engineered to form antigen-b

54 ation and lysosomal shuttling of IgM via its Fc fragment (Fcmu).

55 ic NMO-IgG, preventing cytotoxicity, and the Fc fragments generated by IdeS cleavage reduced CDC and

56 ti-coagulant activity, small oligosaccharide fCS fragments had much reduced anticoagulant properties,

57 The Fc fragments have distinct binding properties for FcRn t

58 sed of hepatitis B surface protein and IgG2a Fc fragment (HBS-Fc-lv) to increase the magnitude of CD8

59 mise the relative arrangement of the Fab and Fc fragments held in a fixed orientation resembling that

60 Characteristic Fab and Fc fragment immobilized patterns served as controls.

61 revealed that, compared with HBS-lv without Fc fragment, immunization with HBS-Fc-lv markedly increa

62 pendent of FcgammaRIIb or sialylation of the Fc fragment in the human setting.

63 the increased C1q binding to galactosylated Fc fragments in human polyclonal IgG.

64 structure of the arrangement of the Fab and Fc fragments in IgA2m(1) was found to be predominantly T

65 olution structure arrangement of the Fab and Fc fragments in IgD is principally T-shaped and flexible

66 Treatment with this omalizumab-resistant IgE-Fc fragment, in combination with omalizumab, promotes th

67 lpha ligands through injection of PDGFRalpha-Fc fragments, inhibit the migration of mesoderm cells af

68 eptidase, cleaves human IgG into F(ab')2 and Fc fragments inhibiting complement-dependent cytotoxicit

69 ch that the end-to-end distance of the bound Fc fragment is greater than it is in the crystal structu

70 Sialylation of the Fc fragment is mediated by beta-galactoside alpha2,6-sia

71 that generally does not require the antibody Fc fragment, likely plays an important role in the prote

72 les contain glycans in the CH2 domain of the Fc fragment (N-glycosylation) which are highly heterogen

73 the similar SpA B domain in complex with the Fc fragment of a human IgG antibody, where helix 3 is no

74 omain of a receptor, an enzyme, etc.) to the Fc fragment of a monoclonal antibody.

75 SCR 1-2 domain pair was engineered with the Fc fragment of a mouse IgG1 antibody to create a chimaer

76 which bind immunoglobulins (Ig) such as the Fc fragment of human IgG (IgG Fc) in a nonimmune manner.

77 fic binding of the recombinant enzyme to the Fc fragment of human IgG, a characteristic that may play

78 reversible interactions of protein A and the Fc fragment of human IgG, detection limits were determin

79 c receptor (FcgammaRIIIB) in complex with an Fc fragment of human IgG1 determined from orthorhombic a

80 The hinge region on the Fc fragment of human immunoglobulin G interacts with at

81 lity complex class II T-cell epitopes in the Fc fragment of IgG that are capable of specifically acti

82 The interaction between a SpA domain and the Fc fragment of IgG was partially elucidated previously i

83 nts between the B domain (Fb) of SpA and the Fc fragment of IgG were identified from the x-ray crysta

84 tly related to FcgammaRI (receptor I for the Fc fragment of IgG) and is encoded on human chromosome 1

85 cRn-mediated transcytosis was blocked by the Fc fragment of IgG, but not F(ab')(2).

86 ll spread of virus and is a receptor for the Fc fragment of IgG.

87 groups that binds with high affinity to the Fc fragment of IgG.

88 III (FVIII) product that when fused with the Fc fragment of IgG1 results in significantly prolonged h

89 , N-, or P-cadherin ectodomains fused to the Fc fragment of immunoglobulin (E-cad/Fc, N-cad/Fc, and P

90 Receptors for the Fc fragment of immunoglobulin G (Fc gammaRs) play a cruc

91 rystal structure for the complex between the Fc fragment of immunoglobulin G (IgG) and the neonatal F

92 Certain Escherichia coli strains bind the Fc fragment of immunoglobulin G (IgG) at the bacterial c

93 Sialylated forms of the Fc fragment of immunoglobulin G, produced by the human a

94 factor VIII (rFVIII) product fused with the Fc fragment of immunoglobulin G1 (IgG1) in 165 patients

95 ated tridecasaccharide 1 associated with the Fc fragment of intravenous immunoglobulin has been synth

96 macrophages act as innate "sensors" for the Fc fragment of IVIG, leading to the induction of Fc gamm

97 Crry with five SCR domains conjugated to the Fc fragment of mouse IgG1 (mCrry-Ig) in order to determi

98 recently showed that interaction between the Fc fragment of the broadly neutralizing antibody IgG1 b1

99 directly by LC-MS, while monkey IgG and the Fc fragment of the recombinant human IgG remained bound

100 ditional intracerebroventricular infusion of Fc fragment of tyrosine kinase receptor B protein (TrkB-

101 The Fc fragments of both human and sheep immunoglobulin G (I

102 Mice injected with IgA1P (1-10 mg/kg) had Fc fragments of IgA1 in both serum and urine, associated

103 The E-domain binds tightly to Fc fragments of IgG and binds certain Fv fragments with

104 Fc fragments of IgG were as active as IgG1, whereas Fab

105 F(ab')2 but not Fc fragments of IVIG induced death of human neutrophils,

106 ntained contiguous fH domains 18-20 fused to Fc fragments of murine IgG2a.

107 the NK-cell surface, as only the immobilized Fc-fragment of GG was required for CD137 expression.

108 impact of FcRn binding characteristics of an Fc fragment on in vivo persistence allows this property

109 ull-length IgE with omalizumab-resistant IgE-Fc fragments on human basophils.

110 t neither binding nor penetration depends on Fc fragments or their cognate receptors.

111 re studies of fCS-selectin interaction using fCS fragments or their mimetics may open new avenues for

112 oinsulin fused with the immunoglobulin (Ig)G Fc fragment (PPI-Fc) is delivered to fetuses through the

113 iodinated minibody and a radioiodinated scFv-Fc fragment produced excellent, high-contrast images in

114 pression of the high-affinity immunoglobulin-Fc fragment receptor I (FcgammaRI) CD64 on neutrophils (

115 Fc fragments released from HIRs-Fc by papain digestion a

116 hy/mass spectrometry analysis of the Fab and Fc fragments revealed several modifications.

117 ed by DcR3-Fc fragment but not control human-Fc fragment, showing that apoptosis occurs via the LIGHT

118 Fcupsilon3-4 is the only nonmammalian Fc fragment structure determined to date and provides th

119 Instead, we find elevation of a Fab+Fc fragment that began with aspartic acid (cleavage betw

120 his structural data to generate a mutant IgE-Fc fragment that is resistant to omalizumab binding.

121 protein of a complement receptor and an IgG Fc fragment, therapeutic outcome was improved in vivo.

122 Addition of TNF-alphaR fused to IgG Fc fragment (TNF-alphaR:Fc) in the presence or absence o

123 The targeting of a glycosylated antibody Fc fragment to bind to cancer cells by site-selective in

124 Although efficient binding of the IgG Fc fragment to cellular FcgammaRs may be essential to ac

125 These data show that modification of the Fc fragment to enhance ADCC can be an effective strategy

126 We also fused V1V2 to an Fc fragment to mimic the unconstrained V1V2 conformation

127 omplement C1q binding (Fc-/-) domains of the Fc fragment to render the Fc unable to direct Ab-depende

128 ng array in which FcRn dimers are bridged by Fc fragments to create an "oligomeric ribbon" with a 2n:

129 in mice between the binding affinity of IgG1/Fc fragments to FcRn at pH 6.0 and their serum t(1/2).

130 ective doses of intact antibody or monomeric Fc fragments to wild-type or Fcgamma receptor-humanized

131 fused to the human immunoglobulin G1-derived Fc fragment under the control of the beta-PHASEOLIN seed

132 affinities of a deglycosylated IgG1 and its Fc fragment were determined by solution binding studies

133 The two SCR domains and the Fc fragment were joined by randomised conformational pep

134 es, to which homology models for the Fab and Fc fragments were connected to generate 10,000 full mode

135 es, to which homology models for the Fab and Fc fragments were connected.

136 scein antibody (4-4-20) and antibody Fab and Fc fragments were immobilized from solution onto respect

137 nstrained by homology models for the Fab and Fc fragments were used to model the experimental IgA1 sc

138 ugar residues and amino acid residues in the Fc fragment, which in turn may impact antibody effector

139 ression system, we generated an IgG1-derived Fc fragment with a C-terminal selenocysteine in yields c

140 We show that engineered Fc fragments with increased affinities for FcRn at pH 6.

141 n of labeled IgG with an excess of unlabeled Fc fragment yielded a small yet significant increase in